Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on September 8, 2014, reporting events occurring on September 4, 2014. The company is a Delaware corporation focused on developing and commercializing pharmaceutical products.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance data.
Material Changes
The material event reported is the issuance of a fourth patent by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR, the company's novel once-daily extended-release oxcarbazepine product.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the patent issuance. The event is categorized under "Other Events" (Item 8.01).
Investor Verification Checklist
- Verify the specific claims and scope of the fourth USPTO patent for Oxtellar XR.
- Review the full text of the press release (Exhibit 99.1) for details on the patent's impact on market exclusivity.
- Confirm the current regulatory status and commercial launch timeline for Oxtellar XR.